Parkinson's Disease (PD) Clinical Trial
Official title:
An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to continue testing whether ABBV-951 is safe, effective, and tolerable in participants with Parkinson's disease after completion of the parent study M15-741. ABBV-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (LDP/CDP) given as infusion under the skin for the treatment of Parkinson's Disease. Participants who have successfully completed M15-741 study will immediately enter this study's treatment period to continue receiving ABBV-951. Adult participants with advanced PD will be enrolled. Approximately 130 adult participants will be enrolled in the study at approximately 65 sites worldwide. Participants will receive continuous subcutaneous infusion (CSCI) of ABBV-951 for 24 hours daily during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular clinic visits and have remote assessments completed via phone calls during the course of the study. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02170376 -
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT02169479 -
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
|
Phase 1 | |
| Completed |
NCT02169895 -
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
|
Phase 1 | |
| Completed |
NCT02778594 -
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
|
Phase 1 | |
| Completed |
NCT02274766 -
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
|
Phase 3 | |
| Completed |
NCT02169453 -
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
|
Phase 1 | |
| Completed |
NCT04380142 -
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
|
Phase 3 | |
| Withdrawn |
NCT06118294 -
Efficacy of Probiotics for Parkinson Disease (PD)
|
N/A | |
| Recruiting |
NCT05916157 -
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
|
||
| Completed |
NCT03033498 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT02169427 -
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
|
Phase 1 | |
| Completed |
NCT02834507 -
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
|
Phase 2 | |
| Completed |
NCT02169440 -
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
|
Phase 1 | |
| Completed |
NCT02202551 -
Open-Label Safety Study of ADS-5102 in PD Patients With LID
|
Phase 3 | |
| Completed |
NCT01398748 -
Intranasal Glutathione in Parkinson's Disease
|
Phase 1 | |
| Recruiting |
NCT06107426 -
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
|
||
| Completed |
NCT02169466 -
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
|
Phase 1 | |
| Recruiting |
NCT03732898 -
Coordinated Reset Deep Brain Stimulation
|
N/A | |
| Completed |
NCT02799381 -
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
|
Phase 3 | |
| Terminated |
NCT03829657 -
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
|
Phase 3 |